Thrivent Financial for Lutherans Buys 14,444 Shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT)

Thrivent Financial for Lutherans boosted its stake in shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT) by 2.3% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 639,332 shares of the biotechnology company’s stock after purchasing an additional 14,444 shares during the quarter. Thrivent Financial for Lutherans owned about 0.67% of Sarepta Therapeutics worth $77,736,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in the stock. Corient Private Wealth LLC bought a new position in Sarepta Therapeutics during the fourth quarter worth $786,000. CBIZ Investment Advisory Services LLC boosted its position in Sarepta Therapeutics by 163.2% during the fourth quarter. CBIZ Investment Advisory Services LLC now owns 587 shares of the biotechnology company’s stock worth $71,000 after purchasing an additional 364 shares during the period. Commonwealth Equity Services LLC boosted its position in Sarepta Therapeutics by 22.1% during the fourth quarter. Commonwealth Equity Services LLC now owns 6,357 shares of the biotechnology company’s stock worth $773,000 after purchasing an additional 1,151 shares during the period. Erste Asset Management GmbH boosted its position in Sarepta Therapeutics by 11.3% during the fourth quarter. Erste Asset Management GmbH now owns 708,248 shares of the biotechnology company’s stock worth $86,116,000 after purchasing an additional 72,183 shares during the period. Finally, Swiss National Bank boosted its position in Sarepta Therapeutics by 1.6% during the fourth quarter. Swiss National Bank now owns 168,783 shares of the biotechnology company’s stock worth $20,522,000 after purchasing an additional 2,700 shares during the period. 86.68% of the stock is owned by institutional investors.

Sarepta Therapeutics Stock Down 27.4 %

Shares of NASDAQ SRPT opened at $73.54 on Wednesday. The company has a current ratio of 3.84, a quick ratio of 3.03 and a debt-to-equity ratio of 0.93. The company has a market cap of $7.14 billion, a price-to-earnings ratio of 58.83 and a beta of 0.79. Sarepta Therapeutics, Inc. has a 12 month low of $73.06 and a 12 month high of $173.25. The stock has a 50-day moving average price of $110.18 and a two-hundred day moving average price of $119.13.

Wall Street Analysts Forecast Growth

A number of equities analysts have commented on the stock. Royal Bank of Canada reduced their price objective on shares of Sarepta Therapeutics from $165.00 to $161.00 and set an “outperform” rating for the company in a research report on Thursday, February 27th. Cantor Fitzgerald reissued an “overweight” rating and issued a $163.00 target price on shares of Sarepta Therapeutics in a research report on Tuesday. StockNews.com cut shares of Sarepta Therapeutics from a “buy” rating to a “hold” rating in a research report on Wednesday, November 20th. Piper Sandler reduced their target price on shares of Sarepta Therapeutics from $200.00 to $182.00 and set an “overweight” rating for the company in a research report on Wednesday, November 27th. Finally, Scotiabank assumed coverage on shares of Sarepta Therapeutics in a research report on Friday, March 7th. They issued a “sector perform” rating and a $105.00 target price for the company. One investment analyst has rated the stock with a sell rating, four have assigned a hold rating, eighteen have assigned a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $170.23.

Insiders Place Their Bets

In other Sarepta Therapeutics news, Director Claude Nicaise sold 2,491 shares of the business’s stock in a transaction dated Wednesday, March 12th. The stock was sold at an average price of $99.64, for a total transaction of $248,203.24. Following the completion of the transaction, the director now owns 27,812 shares of the company’s stock, valued at approximately $2,771,187.68. The trade was a 8.22 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders own 7.70% of the company’s stock.

About Sarepta Therapeutics

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.